

IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1. – 7. (Cancelled)
8. (Currently amended) A method for prevention and/or treatment of a Parkinson's plus syndrome in a patient, comprising administering to the patient a compound selected from the group consisting of rotigotine, a physiologically acceptable ~~[[salts]]~~ salt of rotigotine, and a rotigotine ~~prodrugs~~ prodrug.
9. (Currently amended) The method of claim 8 wherein the Parkinson's plus syndrome is selected from the group consisting of a multiple system ~~atrophies~~ atrophy, progressive supranuclear palsy, corticobasal degeneration, diffuse dementia with Lewy bodies, and a combination ~~combinations~~ thereof.
10. (Currently amended) The method of claim 8, wherein the ~~Parkinson's plus syndrome comprises a failure of the~~ patient fails to respond to L-dopa treatment.
11. (Previously presented) The method of claim 8, wherein the compound is administered orally, parenterally, transdermally or transmucosally.
12. (Previously presented) The method of claim 8, wherein the compound provides an extensively constant plasma level of rotigotine in the plasma of the patient over an application interval.
13. (Previously presented) The method of claim 11, wherein the compound is administered transdermally.
14. (Previously presented) The method of claim 8, wherein the compound is administered to provide a rotigotine dosage of 0.05 mg to approximately 50 mg per day.

15. (Previously presented) The method of claim 8, wherein the compound is administered to provide a plasma level of rotigotine between 0.01 and 50 ng/mL.
16. (Previously presented) The method of claim 15, wherein the rotigotine achieves a steady-state plasma level.
17. (Previously presented) The method of claim 8, wherein the compound is administered to provide a plasma level of rotigotine between 0.05 and 20 ng/mL.
18. (Previously presented) The method of claim 8, wherein the compound is administered to provide a plasma level of rotigotine between 0.1 and 10 ng/mL.
19. (Previously presented) The method of claim 8, wherein rotigotine is administered in the form of a prodrug that is an ether, ester, thiocarbonyl ester, carbamate, thiocarbamate, carbonate, acetal, ketal, acyloxy alkyl ether, oxythiocarbonyl ester, phosphate, phosphonate, sulfate, sulfonate or silylether of rotigotine.
20. (Previously presented) The method of claim 19, wherein the prodrug is a C₁₋₆ alkyl carbonyl ester of rotigotine.
21. (Previously presented) The method of claim 8, wherein the compound is rotigotine hydrochloride.
22. (Previously presented) The method of claim 8, further comprising administering at least one further active agent effective for prevention and/or treatment of the Parkinson's plus syndrome.
23. (Previously presented) The method of claim 22, wherein the compound and the at least one further active substance are separate and are administered to the patient simultaneously.
24. (Previously presented) The method of claim 22, wherein the compound and the at least one further active substance are separate and are administered to the patient in a temporally graduated manner.

25. (Withdrawn) A therapeutic combination comprising rotigotine or a physiologically acceptable salt or prodrug thereof and at least one further active substance that prevents or reduces the rate of progression of dopaminergic cell loss in a patient.
26. (Withdrawn and currently amended) The therapeutic combination of claim 25, wherein the at least one further active substance is selected from the group consisting of antiapoptotic ~~substances~~ **substance, a neurotrophin neurotrophins**, and **a combination combinations** thereof.
27. (Withdrawn and currently amended) The therapeutic combination of claim 26, wherein the at least one further active substance is an antiapoptotic substance selected from the group consisting of minocyclin, FK-506, cyclosporin A, zVAD, and **a combination combinations** thereof.
28. (Withdrawn) The therapeutic combination of claim 26, wherein the at least one further active substance is a neurotrophin comprising glial cell derived neurotrophic factor (GDNF).
29. (Withdrawn) A pharmaceutical form comprising the therapeutic combination of claim 25, wherein the rotigotine has a different release profile than the at least one further active substance.
30. (Withdrawn) The pharmaceutical form of claim 29, wherein the pharmaceutical form is an oral tablet comprising a first portion comprising rotigotine and at least one additional portion comprising the at least one further active substance.
31. (Withdrawn) A kit for treatment and/or prevention of a Parkinson's plus syndrome in a patient, the kit comprising a first medicinal preparation comprising rotigotine or a physiologically acceptable salt or prodrug thereof and a second medicinal preparation comprising at least one further active substance that prevents or reduces the rate of progression of dopaminergic cell loss in a patient.